RemeGen (SEHK:9995): Assessing Valuation After Shanghai Health Care Index Inclusion

Simply Wall St.12-18

RemeGen (SEHK:9995) has just been added to the Shanghai Stock Exchange Health Care Sector Index, a change that puts the biotech directly on the radar of sector trackers and index-linked funds. See our...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592018831?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-12-18 22:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592018831","market":"hk","top_or_hot":-1,"title":"RemeGen (SEHK:9995): Assessing Valuation After Shanghai Health Care Index Inclusion","media":"Simply Wall St.","content":"<div>\n<p>RemeGen (SEHK:9995) has just been added to the Shanghai Stock Exchange Health Care Sector Index, a change that puts the biotech directly on the radar of sector trackers and index-linked funds. See our...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-assessing-valuation-after-shanghai-health-c\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RemeGen (SEHK:9995): Assessing Valuation After Shanghai Health Care Index Inclusion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRemeGen (SEHK:9995): Assessing Valuation After Shanghai Health Care Index Inclusion\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-18 22:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-assessing-valuation-after-shanghai-health-c><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>RemeGen (SEHK:9995) has just been added to the Shanghai Stock Exchange Health Care Sector Index, a change that puts the biotech directly on the radar of sector trackers and index-linked funds. See our...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-assessing-valuation-after-shanghai-health-c\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-assessing-valuation-after-shanghai-health-c","article_id":"2592018831","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9995/remegen-shares/news/remegen-sehk9995-assessing-valuation-after-shanghai-health-c","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592018831","pubTimestamp":1766067199,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"RemeGen (SEHK:9995) has just been added to the Shanghai Stock Exchange Health Care Sector Index, a change that puts the biotech directly on the radar of sector trackers and index-linked funds.\nSee our latest analysis for RemeGen.\nThe latest index inclusion comes after a sharp run, with the year to date share price return of 468.99% and a 396.12% one year total shareholder return now giving way to softer short term momentum as traders reassess risk and future growth.\nIf RemeGen’s surge has you...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK1574":"生物医药B类股","09995":"荣昌生物","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"瑞美根（SEHK：9995）：评估纳入上海医疗保健指数后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":0.9,"DCF":1},"content_text":"RemeGen (SEHK:9995) has just been added to the Shanghai Stock Exchange Health Care Sector Index, a change that puts the biotech directly on the radar of sector trackers and index-linked funds. See our latest analysis for RemeGen. The latest index inclusion comes after a sharp run, with the year to date share price return of 468.99% and a 396.12% one year total shareholder return now giving way to softer short term momentum as traders reassess risk and future growth. If RemeGen’s surge has you rethinking healthcare exposure, it could be worth exploring other healthcare stocks that might balance breakthrough potential with more stable performance profiles. With the stock up nearly fivefold in a year and trading only slightly below analyst targets but at a sizeable discount to some intrinsic estimates, investors now face a key question: is there still a buying opportunity, or is the market already pricing in RemeGen’s next leg of growth? Price-to-Sales of 17.3x: Is it justified? RemeGen trades at a steep 17.3x price to sales multiple, well above peers, despite a last close of HK$76.7 that sits below some intrinsic estimates. Price to sales compares the company’s market value to its trailing twelve month revenue, a common yardstick for high growth, loss making biotechs where earnings are still negative. At 17.3x sales versus the estimated fair price to sales ratio of 14.1x, the market is assigning a substantial premium that assumes rapid growth will translate into future profitability and strong returns on equity. The premium looks even more pronounced against the Hong Kong Biotechs industry average multiple of 12.4x, underscoring how aggressively investors are valuing each dollar of RemeGen’s current revenue. Explore the SWS fair ratio for RemeGen Result: Price-to-Sales of 17.3x (OVERVALUED) However, the story could unravel if clinical timelines slip or recent revenue and earnings growth of 26.9% and 68.6% prove unsustainable. Find out about the key risks to this RemeGen narrative. Another View on Value While the 17.3x price to sales ratio looks stretched against peers, our DCF model paints a different picture, suggesting fair value nearer HK$109.2 per share, around 29.8% above today’s HK$76.7 level. Is the market underestimating RemeGen’s longer term cash generation? Look into how the SWS DCF model arrives at its fair value. 9995 Discounted Cash Flow as at Dec 2025Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out RemeGen for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 908 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.  Build Your Own RemeGen Narrative If you reach different conclusions or want to dig into the numbers yourself, you can quickly build a custom view in under three minutes. Do it your way A great starting point for your RemeGen research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision. Ready for your next high conviction idea? Skip the noise and use Simply Wall Street’s powerful Screener to spot focused opportunities that fit your strategy before everyone else is talking about them.  Target reliable income streams with these 13 dividend stocks with yields > 3% that combine attractive yields with fundamentals strong enough to support long term payouts. Ride the next wave of innovation by scanning these 26 AI penny stocks positioned at the heart of machine learning breakthroughs and real world AI adoption. Strengthen your portfolio’s resilience by hunting for these 908 undervalued stocks based on cash flows where prices still lag behind their underlying cash flow potential.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTechNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592018831","isCrawlerRequest":true}